Investigational drug · Phase 2
HH-006
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis B Virus Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HH-006"
First trial start
2026
May 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HH-006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B Virus Infection
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "HH-006" as an intervention, largest first.
Huahui HealthIndustry
NCT07519330 · 45 participants (planned) · Start May 14, 2026 · Primary completion Feb 28, 2028
Drug: HH-006 · For: Chronic Hepatitis B Virus Infection
Sites: Chongqing, China
Huahui HealthIndustry
NCT07515209 · 36 participants · Start Dec 20, 2024 · Primary completion Dec 15, 2025
Drug: HH-006; 0.9% normal saline · For: Chronic Hepatitis B Virus Infection
Sites: Guangzhou, China · 3 sites in all
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy VolunteersCompleted
Huahui HealthIndustry
NCT05275465 · 33 participants · Start May 3, 2022 · Primary completion Dec 29, 2022
Drug: HH-006; Placebo · For: Hepatitis B
Sites: Brisbane, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Hepatitis B Virus Infection
- ElebsiranVIR-2218, BRII-835Phase 38 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- DaplusiranTomligisiranPhase 21 trial
GSK · Chronic Hepatitis B Virus Infection, Hepatitis B
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.